EFNA4 and neoplasm: Since ephrin-A4 was shown to be abundant in tumour-inducing or stem-like cells in triple-negative (TN) breast and ovarian patient-derived tissues, an ADC against ephrin-A4 was created using the humanised mAb E22 fused to the DNA-damaging agent calicheamicin.